Innoce announced that the company carried out a continuous risk assessment of Sinopharm Group Finance Co., Ltd. As of June 30, 2026, Sinopharm Finance Company had a registered capital of 2200 billion yuan, assets of 48.47 billion yuan, and achieved operating income of 377 million yuan. All regulatory indicators met the requirements of the regulations, the internal control system was sound and implementation was effective, and there were no major flaws in risk management. As of June 30, 2026, the company's deposit balance with Sinopharm Finance Corporation was 244 million yuan. There was no loan or bill related business, deposit safety and liquidity were good, and related financial business risks were manageable.

Innoce announced that the company carried out a continuous risk assessment of Sinopharm Group Finance Co., Ltd. As of June 30, 2026, Sinopharm Finance Company had a registered capital of 2200 billion yuan, assets of 48.47 billion yuan, and achieved operating income of 377 million yuan. All regulatory indicators met the requirements of the regulations, the internal control system was sound and implementation was effective, and there were no major flaws in risk management. As of June 30, 2026, the company's deposit balance with Sinopharm Finance Corporation was 244 million yuan. There was no loan or bill related business, deposit safety and liquidity were good, and related financial business risks were manageable.